Barclays Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Key Points

• Barclays raised its Humana price target to $587 from $582 and maintained an “overweight” rating, implying potential upside of about 35% from the stock’s then-current price.
• Analyst views are broadly positive: MarketBeat’s consensus is “Moderate Buy,” with a $462.87 average price target; 21 analysts rate the stock Buy, 10 Hold, and one Sell.
• Humana’s latest quarterly results beat estimates, with EPS of -$0.70 versus -$1.00 expected and revenue of $41.16 billion versus $40.87 billion expected. Revenue increased 26.1% year over year.

Humana (NYSE:HUM - Get Free Report) had its price target boosted by research analysts at Barclays from $582.00 to $587.00 in a report issued on Monday, Benzinga reports. The firm presently has an "overweight" rating on the insurance provider's stock. Barclays's price objective points to a potential upside of 35.35% from the stock's current price.

Several other research analysts also recently issued reports on the stock. Raymond James Financial reiterated an "outperform" rating on shares of Humana in a research note on Friday. TD Cowen raised their price target on shares of Humana from $350.00 to $370.00 and gave the company a "hold" rating in a research report on Friday, July 31st. HSBC downgraded shares of Humana to a "hold" rating in a research report on Thursday, July 30th. Jefferies Financial Group restated a "buy" rating and issued a $420.00 price objective on shares of Humana in a report on Friday. Finally, Guggenheim upped their price objective on Humana from $471.00 to $521.00 and gave the company a "buy" rating in a research report on Monday. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Humana has a consensus rating of "Moderate Buy" and a consensus price target of $462.87.

Humana Stock Down 0.0%

Shares of NYSE HUM traded down $0.05 during trading on Monday, reaching $433.69. The company had a trading volume of 637,112 shares, compared to its average volume of 1,637,193. Humana has a 12-month low of $163.11 and a 12-month high of $456.50. The stock has a market cap of $52.08 billion, a PE ratio of 42.32, a P/E/G ratio of 2.67 and a beta of 0.65. The business's 50-day moving average is $403.96 and its 200 day moving average is $312.27. The company has a quick ratio of 1.74, a current ratio of 1.65 and a debt-to-equity ratio of 0.61.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.30. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company's revenue was up 26.1% on a year-over-year basis. During the same period last year, the company earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities analysts forecast that Humana will post 9.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Humana during the 2nd quarter valued at $4,138,160,000. Pzena Investment Management LLC bought a new stake in shares of Humana in the second quarter worth $1,749,014,000. Assenagon Asset Management S.A. grew its holdings in shares of Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock worth $479,053,000 after acquiring an additional 1,249,272 shares during the period. Legal & General Group Plc purchased a new stake in Humana during the second quarter valued at $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Humana during the second quarter valued at $314,922,000. Institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.

The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Humana was founded in 1961 as a nursing home company and later expanded into health insurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.